FRI0164 Antibodies to proteinase-3, myeloperoxidase and b2gpi

Abstract

Background Objectives To investigate the relationship between antibodies to proteinase-3 (anti-PR3), myeloperoxidase (anti-MPO) and b2GPI (anti-b2GPI) in patients (pts) with systemic vasculitis and primary antiphospholipid syndrome (PAPS). Methods The sera from 18 pts with polyarteritis nodosa (PAN), 18 pts with Takayasu’s arteritis (TA), 21 pts with thromboangiitis obliterans (TAO), 21 pts with Henoch-Schonlein purpura (HSP), 20 pts with Wegener’s granulomatosis (WG) (ACR,1990) and 8 pts with define PAPS (1998) and 20 donors were surveyed. IgG anti-PR3, anti-MPO and anti-b2GPI by ELISA (Orgentec, Germany) were studied. Results anti-PR3 in 1 (5,6%) pts with PAN and in 3 (14,3%) pts with HSP in low titers were found. anti-PR3 in 13 (61,9%) of 21 pts with WG (in 10 (71,4%) of 14 pts with generalized and in 3 (50%) of 6 local forms) in medium or high titers were observed. anti-MPO in 1 (5,6%) pts with PAN, in 2 (11,2%) pts with TA, in 1 (4,8%) pts with TAO and in 3 (14,3%) pts with HSP in low titers were found. anti-b2GPI in low titers in 4 (22,4%) pts with HSP and in medium or high titers in 8 (100%) pts with PAPS were observed only. anti-PR3 and anti-MPO in 1 pts sera with PAN were attended simultaneously. In HSP 1 pts had anti-PR3, anti-MPO, anti-b2GPI and 1 pts had anti-PR3 and anti-b2GPI simultaneously as well. In the serum from pts with TA, TAO, WG and PAPS anti-PR3 or anti-MPO or anti-b2GPI were attended alone. Conclusion So, in some pts with PAN and HSP anti-MPO, anti-PR3 and anti-b2GPI in low titers are attended simultaneously but their clinical significance are not obscure.